CDC Anticipated: US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19, other Respiratory Virus Vaccines to Prevent Acute Illness in Ambulatory Settings

Sponsor Deadline: 

Feb 2, 2022


Centers for Disease Control and Prevention

UI Contact: 

CDC Forecasted:  US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
estimated posting date: Dec. 1, 2021

CDC solicitations are usually limited to one application per institution. 
Please refer to this link on the UIowa Limited Submissions process (link is external)
Anticipated Internal UI deadline is 30 days prior to sponsor's deadline.

Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza and novel vaccines, such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed in order to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to support a network of US institutions that can: a) conduct systematic testing for laboratory-confirmed disease due to influenza, SARS-CoV-2 and other respiratory virus infections, b) obtain reliable vaccination information for enrolled patients and c) provide accurate estimates of the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2 and other respiratory viruses, to prevent medically attended influenza-associated illness in the population for whom vaccination is recommended.